Continuous Bioprocessing Market Projected to Reach $1.64 Billion by 2034, Driven by Biologics Manufacturing Demand
核心洞察
The global continuous bioprocessing market was valued at USD 386.89 million in 2025 and is forecast to grow at a CAGR of 17.44% through 2034.
Monoclonal antibodies (搜索) accounted for the largest application segment at 35.94% market share in 2025, reflecting the dominance of mAb manufacturing.
North America led the market with a 38.65% revenue share in 2025, while Asia Pacific is expected to grow fastest at a 19.10% CAGR.
The global continuous bioprocessing market is poised for significant expansion, with a valuation of USD 386.89 million in 2025 and a projected climb to USD 1,641.09 million by 2034, reflecting a compound annual growth rate (CAGR) of 17.44% over the forecast period from 2026 to 2034, according to a report by Straits Research.
Continuous bioprocessing represents an advanced biomanufacturing approach that integrates upstream and downstream operations into a seamless, uninterrupted production workflow for biologics, including monoclonal antibodies (搜索), vaccines, recombinant proteins, and cell therapies. The technology enables manufacturers to enhance process efficiency, optimize facility utilization, and maintain high product quality while meeting stringent regulatory compliance standards.
Market Drivers and Regional Dynamics
The rising tide of biologics production, coupled with growing investments in biopharmaceutical manufacturing infrastructure, is fueling demand for cost-efficient, high-productivity processes. Manufacturers are increasingly adopting advanced automation, single-use technologies, and integrated systems to streamline operations.
North America commanded a dominant 38.65% share of the global market in 2025. The U.S. market alone was valued at USD 130.69 million in 2025 and is projected to reach USD 153.25 million in 2026. The Asia Pacific region is expected to be the fastest-growing market, with a projected CAGR of 19.10% during the forecast period. Japan's market was valued at USD 12.84 million in 2025, with projections reaching USD 15.07 million in 2026.
Segmentation Insights
By product, the consumables and reagents segment is anticipated to grow at a CAGR of 18.25% over the forecast period, underscoring the recurring revenue streams tied to continuous processing workflows.
Monoclonal antibodies (搜索) dominated the application landscape, capturing 35.94% of the market share in 2025. This reflects the central role of mAb manufacturing in the biopharmaceutical industry and the suitability of continuous processing for large-scale antibody production.
Contract research organizations (CROs) and contract manufacturing organizations (CMOs) represent the fastest-growing end-use segment, with an expected CAGR of 18.73%. This growth is driven by increasing outsourcing of biologics manufacturing as sponsors seek specialized expertise and scalable capacity.
Competitive Landscape and Strategic Developments
The competitive landscape is moderately consolidated, with key players including Thermo Fisher Scientific (搜索), Danaher Corporation (搜索), Sartorius AG (搜索), Lonza Group (搜索), Repligen Corporation, and FUJIFILM Diosynth Biotechnologies (搜索). Companies compete through continuous processing innovations, automation capabilities, integrated single-use solutions, and strategic partnerships with biopharmaceutical manufacturers.
Several notable industry developments have shaped the market. In September 2025, Thermo Fisher Scientific (搜索) completed the acquisition of Solventum's Purification & Filtration business for approximately USD 4.0 billion, strengthening its bioprocessing and filtration portfolio for biologics manufacturing. In December 2025, Samsung Biologics announced the planned acquisition of a U.S. manufacturing facility in Rockville, Maryland, expanding its global CDMO manufacturing footprint and reinforcing supply chain resilience. Additionally, in August 2025, WuXi Biologics launched the WuXia293 Stable cell line platform to support development and commercial manufacturing of difficult-to-express biologics, further expanding its advanced bioprocessing technology portfolio.
The market ecosystem continues to be driven by increasing biologics production volumes, stringent regulatory requirements, advancements in process analytical technologies, growing adoption of digital manufacturing, and rising demand for scalable, cost-efficient, and flexible bioprocessing solutions that improve both manufacturing productivity and product quality.